Cel-Sci Corporation (CVM): Price and Financial Metrics
GET POWR RATINGS... FREE!
CVM Stock Price Chart Interactive Chart >
CVM Price/Volume Stats
|Current price||$3.13||52-week high||$27.28|
|Prev. close||$3.13||52-week low||$2.49|
|Day high||$3.21||Avg. volume||1,414,476|
|50-day MA||$3.51||Dividend yield||N/A|
|200-day MA||$7.60||Market Cap||135.61M|
Cel-Sci Corporation (CVM) Company Bio
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Most Popular Stories View All
CVM Latest News Stream
|Loading, please wait...|
CVM Latest Social Stream
View Full CVM Social Stream
Latest CVM News From Around the Web
Below are the latest news stories about Cel Sci Corp that investors may wish to consider to help them evaluate CVM as an investment opportunity.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT First Quarter Fiscal Year 2022 Financial Results On February 14, 2022, CEL-SCI Corporation (NYSE:CVM) issued a press release and filed Form 10-Q with the SEC reporting first quarter fiscal year 2022 results. CEL-SCI recently announced in October 2021 that the commercial-scale buildout of the company’s Multikine manufacturing
VIENNA, Va., February 14, 2022--CEL-SCI Corporation reports first quarter fiscal 2022 financial results.
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits.
It's been a bruising start to 2022 on Wall Street — and the tumble moved into correction territory Monday morning with the S&P 500 falling about 10% from a recent high. The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2021 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) announced fiscal year 2021 results, filing Form 10-K with the SEC on December 22, 2021. Highlights for the fourth quarter ended September 30, 2021 and to date include: ➢ Phase III results investor call and discussion - June/July 2021 ➢ Letter to
VIENNA, Va., December 22, 2021--CEL-SCI reports fiscal 2021 financial results and clinical & corporate developments.
CVM Price Returns